Grifols Valuation

Is GIKL.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GIKL.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GIKL.Y ($5.79) is trading below our estimate of fair value ($12.32)

Significantly Below Fair Value: GIKL.Y is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GIKL.Y?

Key metric: As GIKL.Y is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GIKL.Y. This is calculated by dividing GIKL.Y's market cap by their current earnings.
What is GIKL.Y's PE Ratio?
PE Ratio	45.9x
Earnings	€161.49m
Market Cap	€6.90b

GIKL.Y key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	14.8x
PEG Ratio	1.5x

Price to Earnings Ratio vs Peers

How does GIKL.Y's PE Ratio compare to its peers?

The above table shows the PE ratio for GIKL.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.8x
EXEL Exelixis	21.1x	15.6%	US$9.8b
HALO Halozyme Therapeutics	13.8x	21.1%	US$5.8b
ALKS Alkermes	11.5x	-12.6%	US$4.6b
BMRN BioMarin Pharmaceutical	36.6x	27.3%	US$12.1b
GIKL.Y Grifols	45.9x	31.3%	US$6.9b

Price-To-Earnings vs Peers: GIKL.Y is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the peer average (20.8x).

Price to Earnings Ratio vs Industry

How does GIKL.Y's PE Ratio compare vs other companies in the US Biotechs Industry?

11 Companies	Price / Earnings	Estimated Growth	Market Cap
ROIV Roivant Sciences	1.8x	-40.6%	US$8.15b
AGIO Agios Pharmaceuticals	4.5x	-56.7%	US$3.07b
INBX Inhibrx Biosciences	0.1x	n/a	US$200.20m
CTMX CytomX Therapeutics	4.9x	-35.8%	US$71.22m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: GIKL.Y is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the US Biotechs industry average (17.2x).

Price to Earnings Ratio vs Fair Ratio

What is GIKL.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GIKL.Y PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	45.9x
Fair PE Ratio	35x

Price-To-Earnings vs Fair Ratio: GIKL.Y is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the estimated Fair Price-To-Earnings Ratio (35x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

-9.2%

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

-10.5%

7.7%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

-5.1%

74.5%